Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL in Major Depressive Disorder
NCT07621237Phase 2Recruiting
- Sponsor
- Tonix Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of Tonmya in major depressive disorder (MDD), sponsored by Tonix Pharmaceuticals. Started Jun 2026; status: recruiting.
02
Drugs
Tonmya
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07621237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621237.